Aquestive Therapeutics Hits New 52-Week High of $6.43

Aquestive Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 6.43 on September 26, 2025. This achievement marks a notable increase from its 52-week low of USD 2.12, reflecting a remarkable one-year performance of 117.03%. In comparison, the S&P 500 has shown a performance of 15.64% during the same period, highlighting Aquestive's strong position within the Pharmaceuticals & Biotechnology industry.
With a market capitalization of USD 606 million, Aquestive operates as a microcap company. The firm has demonstrated impressive financial metrics, including a return on equity of 89.60%. However, it is important to note that the company is currently loss-making, as indicated by the absence of a price-to-earnings ratio and a negative price-to-book ratio of -8.35. Additionally, the company does not offer a dividend yield, and its debt-to-equity ratio stands at -0.84. This recent price movement underscores the dynamic nature of the stock and its performance in the market.